


M13 Reverse priming site Mlu I  
 201 CACA CAGGAA ACAGCTATGA CATGATTAC GCCAAGCTAT TTAGGTGACG CGTTAGAATA  
 GTGT GTCCTT TGTCGATACT G TACTAATG CCGTTTCGATA AATCCACTGC GCAATCTTAT  
  
Nsi I Hind III Kpn I Sac I BamH I Spe I  
 CTC AAGCTAT GCATCAAGCT TGGTACCGAG CTCGGATCCA CTAGTAACGG CCGCCAGTGT  
 GAGTTCGATA CGTAGTTCGA ACCATGGCTC GAGCCTAGGT GATCATTGCC GGCGGTCACA  
  
EcoR I EcoR I Pst I EcoR V  
 GCTGGAATTC AGG **Blunt PCR Product** CCTGAATTCT GCAGATA  
 CGACCTTAAG TCC GGACTTAAGA CGTCTAT  
  
Not I Xho I Nsi I Xba I Apa I T7 promoter/priming site  
 TCCATCACAC TGGCGGCCGC TCGAGCATGC ATCTAGAGGG CCCAATTCCG CCTATAGTGA  
 AGGTAGTGTG ACCGCCGGCG AGCTCGTACG TAGATCTCCC GGGTTAAGCG GGATATCACT  
  
 M13 Forward (-20) priming site  
 GTCGTATTAC AATTCACTGG CCGTCGTTTT ACAACGTCGT GACTGGGAAA ACCCTGGCGT 470  
 CAGCATAATG TTAAGTGACC GGCAGCAAAA GTTTGCAGCA CTGACCCTTT TGGGACCGCA



**Comments for pCR®-Blunt  
3512 nucleotides**

*Lac* promoter/operator region: bases 95-216  
 M13 Reverse priming site: bases 205-221  
*LacZ*-alpha ORF: bases 217-570  
 Multiple Cloning Site: bases 248-393  
 T7 promoter priming site: bases 400-419  
 M13 Forward (-20) priming site: bases 427-442  
 Fusion joint: bases 571-579  
*ccdB* lethal gene ORF: bases 580-882  
 Kanamycin resistance ORF: bases 1231-2025  
 Zeocin resistance ORF: bases 2231-2605  
 pUC origin: bases 2673-3386